Comparable stake leader
T. Rowe Price Investment Management, Inc.
SEC ownership of Denali Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001714899.
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
50/50
Latest evidence
04 Sep 2026
- Public ticker
- DNLI on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
T. Rowe Price Investment Management, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
T. Rowe Price Investment Management, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
04 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001714899
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Denali Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
T. Rowe Price Investment ...
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
50/50
Latest evidence
04 Sep 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: T. Rowe Price Investment Management, Inc.
Showing 1-8 of 50 holder rows.
Quick read
T. Rowe Price Investment Management, Inc. leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens T. Rowe Price Investment Management, Inc.'s linked filing trail.
Comparable ownership
Top 5
T. Rowe Price Investment Manageme...
10%
BAILLIE GIFFORD & CO
7.5%
BlackRock, Inc.
7.2%
FMR LLC
4.2%
WELLINGTON MANAGEMENT GROUP LLP
3.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
Company
|
10%
|
$416,124,546
16,178,963 shares
|
+$197,010,076 | 30 Jun 2026 |
| BAILLIE GIFFORD & CO |
13F
13D/G
Company
|
7.5%
from 13D/G
|
$307,617,116
11,960,230 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.2%
from 13D/G
|
$360,759,342
14,026,413 shares
|
— | 30 Jun 2026 |
| FMR LLC |
13D/G
13F
Company
|
4.2%
|
$128,121,587
6,672,999 shares
|
-$35,777,146 | 31 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
3.9%
|
$82,251,923
5,664,733 shares
|
$0 | 30 Jun 2025 |
| Capital Research Global Investors |
13D/G
13F
Company
|
3.8%
|
$90,373,982
5,477,211 shares
|
$0 | 31 Dec 2024 |
| Peter Scott Chin |
3/4/5
Chief Medical Officer
|
0.13%
|
$4,559,152
204,538 shares
|
-$36,868 | 04 Sep 2026 |
| STATE STREET CORP |
13F
Company
|
4.4%
|
$181,308,099
7,049,304 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$38,676,971.
Buys
$39,977,138
Insiders: 1
Sells
$1,300,167
Insiders: 4
Net
+$38,676,971
Shares: +2,214,580
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 2,285,714
Shares: 71,134
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 18,718 | $0 | $435,303 | -$435,303 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 52,416 | $0 | $864,864 | -$864,864 |
| 9-12 | 2,285,714 | 0 | $39,977,138 | $0 | +$39,977,138 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 22 reporting-owner rows connected to Denali Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
22
Largest Forms 3/4/5 holder
BAKER BROS. ADVISORS LP
Net 12M change
+$38,676,970
Latest report
04 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director | $520,384,888 | +$39,977,138 | +8.3% | Mixed | 03 Jun 2026 |
| Robert Nelsen | Director | $178,327,354 | Mixed | 02 Jun 2021 | ||
| Felix Baker | Director | $65,709,427 | Mixed | 03 Jun 2026 | ||
| Baker Bros. Advisors (GP) LLC | Director | $65,709,427 | Mixed | 03 Jun 2026 | ||
| 667, L.P. | Director | $65,709,427 | Mixed | 03 Jun 2026 | ||
| Baker Brothers Life Sciences LP | Director | $65,709,427 | Mixed | 03 Jun 2026 | ||
| Julian C. Baker | Director | $65,709,427 | Mixed | 03 Jun 2026 | ||
| Ryan J. Watts | President and CEO, Director | $62,170,820 | -$580,767 | -0.93% | Median | 12 Aug 2026 |
| Marc Tessier-Lavigne | Director | $34,909,435 | Mixed | 03 Jun 2025 | ||
| Schuth Alexander O | COFO and Secretary | $20,010,466 | -$420,604 | -2.1% | Mixed | 01 Sep 2026 |
| Steve E. Krognes | Director | $15,743,980 | Mixed | 03 Jun 2026 | ||
| Flatley Jay T. | Director | $6,891,666 | Mixed | 03 Jun 2026 | ||
| Peter Scott Chin | Chief Medical Officer | $4,559,152 | -$36,868 | -0.8% | Filing P/S | 04 Sep 2026 |
| Carole Ho | Chief Medical Officer | $3,533,804 | Mixed | 12 Aug 2025 | ||
| Vicki L. Sato | Director | $2,257,778 | Filing P/S | 02 Jan 2025 | ||
| David P. Schenkein | Director | $1,015,622 | Mixed | 03 Jun 2026 | ||
| Peter S. Klein | Director | $651,667 | Mixed | 03 Jun 2026 | ||
| Jennifer E. Cook | Director | $623,673 | Mixed | 03 Jun 2026 | ||
| Douglas G. Cole | Director | $489,309 | Mixed | 01 Jun 2023 | ||
| Nancy Thornberry | Director | $467,345 | -$261,929 | -36% | Filing P/S | 02 Sep 2026 |
Recent insider transactions for Denali Therapeutics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Peter Scott Chin | DNLI | Common Stock | Sale | -0.8% | $36,868 | $22.29 | -1,654 | 204,538 | 04 Sep 2026 | Direct |
| Nancy Thornberry | DNLI | Common Stock | Sale | -36.8% | $261,928 | $22.90 | -11,439 | 19,686 | 02 Sep 2026 | Direct |
| Schuth Alexander O | DNLI | Common Stock | Sale | -0.98% | $64,882 | $23.44 | -2,768 | 278,995 | 01 Sep 2026 | Direct |
| Ryan J. Watts | DNLI | Common Stock | Gift | -1.5% | -32,220 | 2,120,384 | 12 Aug 2026 | See footnote | ||
| Schuth Alexander O | DNLI | Common Stock | Sale | -1% | $71,625 | $25.07 | -2,857 | 281,763 | 11 Aug 2026 | Direct |
| Flatley Jay T. | DNLI | Common Stock | Award | 39.5% | 6,408 | 22,628 | 03 Jun 2026 | Direct | ||
| Flatley Jay T. | DNLI | Stock Option (right to buy) | Award | 19,226 | 19,226 | 03 Jun 2026 | Direct | |||
| Peter S. Klein | DNLI | Common Stock | Award | 23.3% | 6,408 | 33,941 | 03 Jun 2026 | Direct | ||
| Peter S. Klein | DNLI | Stock Option (right to buy) | Award | 19,226 | 19,226 | 03 Jun 2026 | Direct | |||
| Steve E. Krognes | DNLI | Common Stock | Award | 20.2% | 6,408 | 38,202 | 03 Jun 2026 | Direct | ||
| Steve E. Krognes | DNLI | Stock Option (right to buy) | Award | 19,226 | 19,226 | 03 Jun 2026 | Direct | |||
| David P. Schenkein | DNLI | Common Stock | Award | 42% | 6,408 | 21,665 | 03 Jun 2026 | Direct | ||
| David P. Schenkein | DNLI | Stock Option (right to buy) | Award | 19,226 | 19,226 | 03 Jun 2026 | Direct | |||
| Nancy Thornberry | DNLI | Common Stock | Award | 25.9% | 6,408 | 31,125 | 03 Jun 2026 | Direct | ||
| Nancy Thornberry | DNLI | Stock Option (right to buy) | Award | 19,226 | 19,226 | 03 Jun 2026 | Direct | |||
| Timothy van Hauwermeiren | DNLI | Common Stock | Award | 60.3% | 6,408 | 17,040 | 03 Jun 2026 | Direct | ||
| Timothy van Hauwermeiren | DNLI | Stock Option (right to buy) | Award | 19,226 | 19,226 | 03 Jun 2026 | Direct | |||
| Jennifer E. Cook | DNLI | Common Stock | Award | 24.6% | 6,408 | 32,483 | 03 Jun 2026 | Direct | ||
| Jennifer E. Cook | DNLI | Stock Option (right to buy) | Award | 19,226 | 19,226 | 03 Jun 2026 | Direct | |||
| BAKER BROS. ADVISORS LP | DNLI | Common Stock | Award | 0.38% | 12,816 | 3,422,366 | 03 Jun 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | DNLI | Common Stock | Award | 0.38% | 12,816 | 3,422,366 | 03 Jun 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | DNLI | Common Stock | Award | 0.38% | 12,816 | 3,422,366 | 03 Jun 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | DNLI | Common Stock | Award | 0.38% | 12,816 | 3,422,366 | 03 Jun 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | DNLI | Common Stock | Award | 0.38% | 12,816 | 3,422,366 | 03 Jun 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | DNLI | Common Stock | Award | 0.38% | 12,816 | 3,422,366 | 03 Jun 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | DNLI | Non-Qualified Stock Option (right to buy) | Award | 38,452 | 19,226 | 03 Jun 2026 | See Footnotes | |||
| BAKER BROS. ADVISORS LP | DNLI | Non-Qualified Stock Option (right to buy) | Award | 38,452 | 19,226 | 03 Jun 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | DNLI | Non-Qualified Stock Option (right to buy) | Award | 38,452 | 19,226 | 03 Jun 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | DNLI | Non-Qualified Stock Option (right to buy) | Award | 38,452 | 19,226 | 03 Jun 2026 | See Footnotes | |||
| BAKER BROS. ADVISORS LP | DNLI | Non-Qualified Stock Option (right to buy) | Award | 38,452 | 19,226 | 03 Jun 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | DNLI | Non-Qualified Stock Option (right to buy) | Award | 38,452 | 19,226 | 03 Jun 2026 | See Footnotes | |||
| Ryan J. Watts | DNLI | Common Stock | Sale | -10.6% | $580,767 | $16.50 | -35,198 | 296,833 | 06 Jan 2026 | Direct |
| Schuth Alexander O | DNLI | Common Stock | Sale | -5.74% | $284,097 | $16.50 | -17,218 | 282,828 | 06 Jan 2026 | Direct |
| Schuth Alexander O | DNLI | Common Stock | Award | 23.8% | 57,700 | 300,046 | 03 Jan 2026 | Direct | ||
| Schuth Alexander O | DNLI | Stock Option (right to buy) | Award | 173,100 | 173,100 | 03 Jan 2026 | Direct | |||
| Ryan J. Watts | DNLI | Common Stock | Award | 31.2% | 78,960 | 332,031 | 03 Jan 2026 | Direct | ||
| Ryan J. Watts | DNLI | Stock Option (right to buy) | Award | 236,880 | 236,880 | 03 Jan 2026 | Direct | |||
| Baker Bros. Advisors Lp | DNLI | $0.01 Prefunded Warrants | Purchase | 9.64% | $39,977,138 | $17.49 | 2,285,714 | 25,996,310 | 11 Dec 2025 | See Footnotes |
| Timothy van Hauwermeiren | DNLI | Common Stock | Award | 10,632 | 10,632 | 04 Nov 2025 | Direct | |||
| Timothy van Hauwermeiren | DNLI | Stock Option (right to buy) | Award | 31,897 | 31,897 | 04 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.